IPO News Archive
Talecris Biotherapeutics prices IPO at $19.00 midpoint, increases deal size by 12%

10/1/09


Talecris Biotherapeutics, a former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, raised $950 million on Wednesday by offering 50 million shares at $19.00, at the midpoint of the $18.00 to $20.00 range. The deal was 12% larger than expected, with selling shareholders Cerberus Capital and Ampersand Ventures offering an additional 5.3 million shares. Talecris Biotherapeutics is expected to begin trading Thursday on the NASDAQ under the symbol TLCR. Morgan Stanley, Goldman Sachs, and Citi acted as lead managers on the deal.

View IPO Profile: TLCR         
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest